What is Swedish Orphan Biovitrum AB Operating Cash Flow per Share?
Swedish Orphan Biovitrum AB's operating cash flow per share for the
three
months ended in Mar. 2025 was kr6.61.
Swedish Orphan Biovitrum AB's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2025 was kr22.01.
During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Swedish Orphan Biovitrum AB was 55.60% per year.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 6.70% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 7.00% per year.
During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 37.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Swedish Orphan Biovitrum AB's Operating Cash Flow per Share or its related term are showing as below:
CHIX:SOBIs'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -91.8 Med: 22.1 Max: 113.2
Current: 6.7
During the past 13 years, Swedish Orphan Biovitrum AB's highest 3-Year average Operating Cash Flow per Share Growth Rate was 113.20% per year. The lowest was -91.80% per year. And the median was 22.10% per year.
CHIX:SOBIs's 3-Year OCF Growth Rate is ranked worse than 52.59% of 772
companies
in the Drug Manufacturers industry
Industry Median: 8.6
vs CHIX:SOBIs: 6.70
Swedish Orphan Biovitrum AB Operating Cash Flow per Share Historical Data
The historical data trend for Swedish Orphan Biovitrum AB's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Swedish Orphan Biovitrum AB Operating Cash Flow per Share Chart
Competitive Comparison of Swedish Orphan Biovitrum AB's Operating Cash Flow per Share
For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Swedish Orphan Biovitrum AB's Price-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Swedish Orphan Biovitrum AB's Price-to-Operating-Cash-Flow falls into.
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr22.01
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Swedish Orphan Biovitrum AB Operating Cash Flow per Share Related Terms
Thank you for viewing the detailed overview of Swedish Orphan Biovitrum AB's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CHIX:SOBIS has been successfully added to your 